Boothbay Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boothbay Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,800	Closed	-$1.93M	–	1667
2023 Q3	$1.93M	Buy	21,800 +1,800	+9%	+$160K	0.05%	516
2023 Q2	$1.73M	Buy	20,000 +11,400	+133%	+$1.07M	0.04%	616
2023 Q1	$836K	Buy	8,600 +6,100	+244%	+$632K	0.02%	1074
2022 Q4	$259K	Sell	2,500 -69,000	-97%	-$6.48M	0.01%	1468
2022 Q3	$6.06M	Buy	+71,500	New	+$6.37M	0.15%	144
2022 Q2	–	Sell	-33,300	Closed	-$2.57M	–	2266
2022 Q1	$2.57M	Buy	33,300 +13,100	+65%	+$1.1M	0.06%	470
2021 Q4	$1.78M	Buy	+20,200	New	+$1.67M	0.04%	515
2020 Q2	–	Sell	-68	Closed	-$574K	–	975
2020 Q1	$574K	Buy	+68	New	+$5.86K	0.05%	431
2019 Q3	–	Sell	-40	Closed	-$343K	–	771
2019 Q2	$343K	Sell	40 -81	-67%	-$6.93K	0.03%	508
2019 Q1	$1.07M	Buy	+121	New	+$11.2K	0.1%	216
2016 Q2	–	Sell	-4,800	Closed	-$396K	–	512
2016 Q1	$396K	Buy	+4,800	New	+$391K	0.3%	104

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's BMRN Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 34,206 shares worth $1.93M. The stake represents 0.03% of the portfolio and ranks #642 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BMRN as recently as Q3 2025.

Boothbay Fund Management first reported a position in BMRN in Q1 2017 and has held it in 12 quarters since. The position peaked at $2.51M in Q1 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Boothbay Fund Management held 34,206 shares of BioMarin Pharmaceuticals worth $1.93M as of Q1 2026.
BioMarin Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
BioMarin Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #642 holding.
Boothbay Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 12 quarters since.
Boothbay Fund Management's BioMarin Pharmaceuticals position peaked at $2.51M in Q1 2023.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.